[1]
Fouad, S.A.; Basalious, E.B.; El-Nabarawi, M.A.; Tayel, S.A. Microemulsion and poloxamer microemulsion-based gel for sustained transdermal delivery of diclofenac epolamine using in-skin drug depot: In vitro/in vivo evaluation. Int. J. Pharm., 2013, 453(2), 569-578.
[2]
Yuan, Y.; Li, S.M.; Yu, L.M.; Deng, P.; Zhong, D.F. Physicochemical properties and evaluation of microemulsion systems for transdermal delivery of meloxicam. Chem. Res. Chin. Univ., 2007, 23(1), 81-86.
[3]
Müller, R.H.; Olbrich, C. Solid lipid nanoparticles: Phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Die Pharmbit, 1999, 61(6), 462-467.
[4]
Weyhersn, H.; Ehlers, S.; Hahn, H.; Souto, E.B.; Müller, R.H. Solid Lipid Nanoparticles (SLN)- effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie, 2006, 61(6), 539-544.
[5]
Müller, R.H.; Mäder, K.; Gohla, S. Solid Lipid Nanoparticles (SLN) for controlled drug delivery- A review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177.
[6]
Radtke, M.; Müller, R.H. Nanostructured lipid carriers (NLC): The new generation of lipid drug carriers. New Drugs, 2001, 2I, 48-52.
[7]
O’Driscoll, C.M. Lipid based formulation for intestinal lymphatic delivery. Eur. J. Pharm. Sci., 2002, 15(5), 405-415.
[8]
Sweetman, S.C. In: Martindale: The Complete Drug Reference; Sweetman, S.C., Ed; 36th ed., Pharmaceutical Press, 2009; pp. 1490-1546.
[9]
Doktorovová, S.; Araújo, J.; Garcia, M.L.; Rakovsky, E.; Souto, E.B. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf. B Biointerfaces, 2010, 75(2), 538-542.
[10]
Chen, C.C.; Tsai, T.H.; Huang, Z.R.; Fang, J.Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm., 2010, 74(3), 474-482.
[11]
Gonzalez-Mira, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf. B Biointerfaces, 2010, 81(2), 412-421.
[12]
Nayak, A.P.; Tiyaboonchai, W.; Patankar, S.; Madhusudhan, B.; Souto, E.B. Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment. Colloids Surf. B Biointerfaces, 2010, 81(2), 263-273.
[13]
Park, J.Y.; Lee, K.; Choi, S.A.; Jeong, M.J.; Kim, B.; Lee, J.S.; Oh, Y.K. Sonication-assisted homogenization system for improved lipid extraction from Chlorella vulgaris. Renew. Energy, 2015, 79, 3-8.
[14]
de Vringer, T. Topical preparation containing a suspension of solid lipid particles. European Patent 91200664,, 1992.
[15]
Wissing, S.A.; Lippacher, A.; Müller, R.H. Investigations on the occlusive properties of Solid Lipid Nanoparticles (SLNTM). J. Cosmet. Sci., 2001, 52(2), 313-323.
[16]
Shen, H.; Zhong, M. Preparation and evaluation of Self-Microemulsifying Drug Delivery Systems (SMEDDS) containing atorvastatin. J. Pharm. Pharmacol., 2006, 58(9), 1183-1191.
[17]
Kumbhar, D.D.; Pokharkar, V.B. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: Physicochemical investigations. Colloids Surf. A Physicochem. Eng. Asp., 2013, 416, 32-42.
[18]
Higuchi, T.; Connors, K.A. Phase-solubility techniques. Adv. Anal. Chem. Inst, 1965, 4, 117-212.
[19]
Jouyban, A. Handbook of solubility data for pharmaceuticals, 1st ed; CRC Press: Taylor and Francis: Boca Raton, 2010.
[20]
Zou, J.J.; Dai, L.; Ding, L.; Xiao, D.W.; Bin, Z.Y.; Fan, H.W.; Liu, L.; Wang, G.J. Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography- positive/negative electrospray ionization tandem mass spectrometry. J. Chromatogr. B, 2008, 873(2), 159-164.
[21]
Simon, A.; Vinícius Borges, R.A.; Cabral, L.M.; Pereira de Sousa, V. Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension. AAPS PharmSciTech, 2013, 14(1), 425-434.
[22]
Zhang, X.; Liu, J.; Qiao, H.; Liu, H.; Ni, J.; Zhang, W.; Shi, Y. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol., 2010, 197(1-2), 120-128.
[23]
Larrucea, E.; Arellano, A.; Santoyo, S.; Ygartua, P. Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur. J. Pharm. Biopharm., 2001, 52(2), 113-119.
[24]
Silva, L.A.D.; Taveira, S.F.; Lima, E.M.; Marreto, R.N. In vitro skin penetration of clobetasol from lipid nanoparticles: Drug extraction and quantitation in different skin layers. Braz. J. Pharm. Sci., 2012, 48(4), 811-817.
[25]
Vitorino, C.; Almeida, J.; Gonçalves, L.M.; Almeida, A.J.; Sousa, J.J.; Pais, A.A. Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail. J. Control. Release, 2013, 167(3), 301-314.
[26]
Patidar, A.; Thakur, D.S.; Kumar, P.; Verma, J. A review on novel lipid based nanocarriers. Int. J. Pharm. Pharm. Sci., 2010, 2(4), 30-35.
[27]
Han, F.; Li, S.; Yin, R.; Liu, H.; Xu, L. Effect of surfactants on the formulation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf. A, 2008, 315(1-3), 210-216.
[28]
Malmsten, M. In: Surfactants and Polymers in Drug
Delivery; Malmsten M, Ed.; 1st ed, CRC Press: New
York, 2002, pp. 164-203.
[29]
Boyadjiev, C. In: Theoretical Chemical Engineering,
Modeling and Simulation; Boyadjiev, C. Ed.; 1st ed.,
Springer Verlag Berlin Heidelberg: New York, 2010;
pp. 127-186.
[30]
Wissing, S.A.; Lippacher, A.; Müller, R.H. Investigations on the occlusive properties of Solid Lipid Nanoparticles (SLNTM). J. Cosmet. Sci., 2001, 52, 313-323.
[31]
Mollet, H.; Grubenmann, A. In: Formulation Technology:
Emulsions, Suspensions, Solid Form; Mollet,
H.; Grubenmann, A.; Ed.; 1st ed., Wiley-VCH Verlag
GmbH: Federal Republic of Germany, 2004; pp. 90-
104.
[32]
Puglia, C.; Frasca, G.; Musumeci, T.; Rizza, L.; Puglisi, G.; Bonina, F.; Chiechio, S. Curcumin loaded nlc induces histone hypoacetylation in the CNS after intraperitoneal administration in mice. Eur. J. Pharm. Biopharm., 2012, 81(2), 288-293.
[33]
Swidan, S.A.; Ghonaim, H.M.; Samy, A.M.; Ghorab, M.M. Comparative study of solid lipid nanoparticles and nanostructured lipid carriers for in vitro paclitaxel delivery. J. Chem. Pharm. Res., 2016, 8(5), 482-493.
[34]
Bunjes, H.; Unruh, T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev., 2007, 59(6), 379-402.
[35]
Motwani, S.K.; Chopra, S.; Talegoankar, S.; Konchan, K.; Ahed, F.J.; Khar, R.K. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur. J. Pharm. Biopharm., 2008, 68(3), 513-525.
[36]
Gwak, H.S.; Chun, I.K. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int. J. Pharm., 2002, 236(1-2), 57-64.